Peanut OIT Aimmune had late breaking news!

At the recent AAAAI allergy national and international meeting in Orlando had many highlights including the late breaking news that AIMMUNE the company researching and producing the peanut oral immunotherapy showed that 67% of the patients being treated were able to tolerate 600mg (about 2 peanuts) without severe reaction! Hoping this treatment will be FDA approved by 2019 and on the market by 2019-2020! Finally an FDA safe and effective treatment for peanut allergic patients may be just around the corner.